Member Info for Vascular

Sorry my post looks out of date.

Looks like Cliff Holloway and Richard GoodFellow will be attending the Basel event. Good to see Moditope listed along with Immunobody listed as industry platforms.

https://www.life-sciences-usa.com/organisation/scancell-group-ltd-oxford-oxfordshire-south-east-england-2001-40499.html

Thanks for sharing Marcus.

Great to hear peeps not connected to Scancell get excited about recent results.

Scancell starts around 17 mins in , I think.

As the next update on the PFS data and early overall survival figures are expected in the first half of 2027 then it’s today’s data that will be crucial to any interested party’s in discussions. It would have been sensible for all interested party’s to wait for today’s update before progressing further in discussions, so with no more data likely to be shared regarding iSCIB1 this year, the efficacy side of the talks is now pretty much confirmed and concluded.

Any interested party’s must now have all the info they require, and hopefully suitably impressed to complete negotiations and hopefully revise their offers.

I just wondered whether party’s in discussions could have had say monthly updates on this data, given to them confidentially etc so that today’s excellent results were already anticipated / expected…meaning talks on terms etc could be more advanced than we realise.

Am I correct in thinking that the fantastic readout from todays RNS , while made public today - could have , or would have already been shared with prospective partners / investors in current discussions, possibly weeks ago.as part of the negotiations ...so as new as this info is to us , crucial decisions based on this information could have already been made in private.......and this is the a crucial step towards full disclosure of partnering / funding news.

Or, alternatively, would those party's in discussions with Scancell only get to see this information today .

Well done, and Congratulations to the Scancell Team

Don’t believe this was posted .

https://joshthompson.co.uk/investing/silver-bullet-first-profitable-quarter-ebitda-positive-q1-2026/

CompaniesHouse have Sath as resigned from GLYMAB THERAPEUTICS LIMITED on 24th April 26

“ NIRMALANANTHAN, Sathijeevan

Correspondence address

The Bellhouse Building, Sanders Road, Oxford Science Park, Oxford, United Kingdom, OX4 4GD

Role RESIGNED

Secretary

Appointed on

24 June 2025

Resigned on

24 April 2026

https://find-and-update.company-information.service.gov.uk/company/16538942/officers

I don’t understand why if ES bought CC tomorrow that ES future opportunities with the newly acquired CC technology and staff ( and keys) would not also benefit ( like CC may do, if they remain independent) . The recent CEA changes in interoperability of meters etc sounds like a even better prospect for ES in India.

Surely the India Gov do not care about CC per se …just care about whoever whoever currently owns the technology will continue to work with the Indian government ( who apparently have part of the key, or something.)

Why so sure the recent CEA changes are a negative for ES, I’m sure they are capable of working along side Indian government if that what it takes.

Anyone else surprised why no other offers from other competitors or partners have been made for CC.

If this drama does eventually come down to a vote by major investors …the issue about .PM selling up, if actually true ,could be the “change” , dependent on who’s buying and why they are buying NOW.

Can’t help but thinking this is progressing as designed too…why else accept an obvious low ball soft offer …no business man can say that’s there finest hour, surely.

All I can say gizmo is that it wasJC decision to take us on this path by not rejecting ES soft offer immediately, so I assume JC wants to sell.

If , I am wrong and he’s playing games now on offer being rejected ..then he’s gambling imo and begs the question WHY, gamble now on a rejection ….when he could have rejected the offer himself earlier…so I’m of the opinion he’s wanting to sell.

Again, I still do not understand as far as the India gov new rules etc how CC would be any better off if at the end of the day this comes to nothing. cC would be same company as of two months ago, same opportunities etc, the new rules would have happened anyway….

I did think at one stage there may be an interval battle between major investors on the decision JC made and if so, with PM selling out , may point towards they are not happy….but who’s buying ?

Appreciate your posts gizmo.

Regarding your post” ....I see a new landscape ....no hidden walled garden ...and a new path with trusted bricks”

Wouldn’t CC presently be on the same path, same better opportunities if JC had ignored the ES offer, killed the soft bid immediately, with a no. The rules have changed in India but that would have happened anyway. Assuming nothing comes from this situation . What added value is this drawn out process adding to CCs opportunities.

All I can think of is we get a snap shot over several months of who owns CC shares.

Hi Chester, Just as a reaction to your. Comment “ Given that we are currently running the SCOPE trial phase 2 under MHRA guidance what could be different or difficult about running the Phase 3 ?“

What If talks / negotiations regarding future of scancell actually involve the Scope phase 3 trial. Probably a very unlikely comment by me, maybe not plausible but is possible , if the phase3 is also on the table. Gl vas

Morning All.

Following the posts here and utterly confused by the logic of opening the door to ES to purchase CC.

The reaction from the BODs on the first , then second offers should have been an outright rejection.

This would have projected a message to market that CC is worth far more than these.

We are now tarnished as a 10p company.

It’s now common knowledge across the industry that potentially CC is for sale ,and the price presently in discussion is very low…., the CC technology and solution is proven in India with a healthy backlog off orders and v. Good future potential - so why no counter offer from another competitor or partner…especially when they only need to beat 10.4 p per share.

Are we now to believe that as no other offers have been made then in-fact 10.4 p is the value of CC today on the Smart Meter industry market! How could anyone say otherwise when it’s for sale and no one is interested in paying more….

Old adage. Something is only worth what people will pay for it.

The argument that CC will be worth say 10 fold in future, say £1 does not really stack up as that would make it even more valuable now at 10p a share, surely. Gl vas

What's bonkers here is the 20% spread. Can hide anything in there!

Disappointed that the decision regarding the National funding is now expected over next nine months . The good news imo is this opportunity is still alive and kicking, and the longer FDBK continue in discussions the more promising the outlook imo.

There is no evidence these delays are related to FDBK ,and were partly expected dealing with the NHS ,going through a once in a generation transformation.

qVH imo will become part of the nhs blueprint along with other successful , continuing projects paid for by the centre.

Morning Mornington.

Yes, try and post the link . Thanks

Not sure if this has been posted here before , even though dated , is a good read for anyone new to, or thinking of investing in FDBK as it covers all the main points imo. Plus emphasises the potential opportunity's here in the next few weeks and months , H1 26.

https://joshthompson.co.uk/investing/feedback-plc-h1-2025-results-bleepa-nhs-national-scale/#:~:text=Interpretation:%20Laying%20Track%20Before%20the,to%20flow%20from%202026/27.

I feel the same as you. Good luck with your most recent purchases. Hopefully your timing will be spot on.

Wonder what made someone suddenly go on a 30k buying spree?

Are they your buys Dibs. :)

From the 5th March Trading update..looking forward…

“ Committed revenues are already at 73% of management's expectations for the full year, with an additional strong pipeline of new business not yet reflected in managements forecasts.”

We know about the European airline, the new significant partner for 4D in the United States and the global marketing and technology partner in the Asia-Pacific region mentioned in 15th April update.

So, am I correct in thinking that the “ additional strong pipeline of New Business” is yet to be disclosed . If so, should be a news rich, revenue enhancing period approaching.